Bloom Michelle, Alvarez-Cardona Jose A, Ganatra Sarju, Barac Ana, Pusic Iskra, Lenihan Daniel, Dent Susan
Leon H. Charney Division of Cardiology, New York University School of Medicine, NYU Langone Health, New York, NY, USA.
Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Department of Medicine, Beth Israel Lahey Health, Burlington, MA, USA.
Cardiooncology. 2024 Sep 28;10(1):63. doi: 10.1186/s40959-024-00259-5.
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
癌症患者的心力衰竭（HF）与高发病率和死亡率相关。癌症治疗的成功导致癌症幸存者数量呈指数级增长，然而，心血管疾病（CVD）现在是癌症诊断后5年以上限制生命的主要疾病[斯特金、邓、布卢斯曼等人，《临床肿瘤学杂志》40(48):3889 - 3897，2019年]。预防和早期发现CVD，包括心肌病（CM）和HF至关重要。欧洲心脏病学会（ESC）发布了心脏肿瘤学（CO）指南[里昂、洛佩斯 - 费尔南德斯、库奇等人，《欧洲心脏杂志》43(41):4229 - 4361，2022年]，详细阐述了在癌症治疗过程中和治疗结束后心血管（CV）风险分层、预防、监测、诊断和治疗。在此，我们通过一个病例总结ESC指南中与HF临床医生相关的方面，重点关注风险分层、早期发现、CM和HF的预防以及指南指导的药物治疗在癌症患者中的作用。
